Hadean invests in $30m round for Attgeno

The deal marks the first investment from Hadean's debut fund, Hadean Capital I, which held a first close on €35m in December 2017.

Other backers in the round include private investors and Swedish investment company Mertiva. As part of the funding round, Hadean will join the board of Attgeno, managing partner Ingrid Teigland Akay told Unquote.

With the fresh capital, the company will finance clinical phase-I studies. Its lead candidate Supernitro targets acute pulmonary hypertension, which may occur in intensive care patients and can lead to a fatal outcome. Supernitro selectively reduces blood pressure in the lungs and thereby has the potential to treat the underlying cause of the acute pulmonary hypertension.

Following the first close of its maiden fund, the Hadean investment team is now expecting a final close within 6-12 months, with a possible interim close beforehand depending on the process, Teigland said.

Company
Headquartered in Stockholm, Attgeno is a drug development company founded by researchers at the Karolinska Institute in Stockholm.

The team has found a method of producing new nitrogen-oxide-containing substances with unique properties. The patented drug candidates have been studied in various animal models of diseases for circulatory system disorders.

People
Hadean Ventures – Ingrid Teigland Akay, Walter Stockinger (managing partners).
Attgeno – Per Agvald (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Nordics
• Healthcare
• Sweden
• Norway
• Venture